Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Champions Oncology, Inc. - Common Stock (NQ:CSBR)

8.810 -0.100 (-1.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Champions Oncology, Inc. - Common Stock

< Previous 1 2 Next >
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Via ACCESS Newswire
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
Via ACCESS Newswire
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine
Via ACCESS Newswire
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million
Via ACCESS Newswire
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
Via ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $13.1 Million
Via ACCESSWIRE
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
Via ACCESS Newswire
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
Via ACCESSWIRE
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
Via ACCESSWIRE
Champions Oncology Announces Agreement with Weill Cornell Medicine
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
Via ACCESSWIRE
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
Via ACCESSWIRE
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
Via ACCESSWIRE
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.0 Million
Via ACCESSWIRE
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
Via ACCESSWIRE
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $11.6 Million
Via ACCESSWIRE
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023
Via ACCESSWIRE
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification
Via ACCESSWIRE
Champions Oncology Announces the Addition of Brady Davis as President
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.6 Million
Via ACCESSWIRE
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 13, 2023
Via ACCESSWIRE
Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023
Via ACCESSWIRE
Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies
Via ACCESSWIRE
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023
Via ACCESSWIRE
Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development
Via ACCESSWIRE
Champions Oncology Announces $5M Stock Repurchase Program
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.